GlassScriptPhysician profile
Tanya Sargent
NPI 1134671720
$3,786.66
in general payments reported to CMS, 2019-2025
23 companies · $1,197 in 2025
The $1,197 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $139 · 2022: $581 · 2023: $610 · 2024: $1,259 · 2025: $1,197.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,001 · Education: $65.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,000.67 |
| Education | $65.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $536.21 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $514.91 | 2022-2025 | Breztri, Airsupra, Farxiga |
| Pfizer INC. | $510.27 | 2023-2025 | |
| Abbott Laboratories | $291.50 | 2022-2025 | Freestyle Libre 3, Proclaim, Freestyle Libre 2 |
| Abbvie INC. | $274.31 | 2022-2025 | |
| Astellas Pharma US INC | $247.63 | 2023-2024 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $227.66 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $186.46 | 2023-2025 | Otezla, Repatha, Repatha |
| Teva Pharmaceuticals USA, INC. | $174.40 | 2021-2024 | Austedo Xr |
| Lilly USA, LLC | $141.83 | 2022-2024 | Mounjaro, Jardiance, Emgality |
| Merck Sharp & Dohme LLC | $141.73 | 2022-2024 | Gardasil 9, Vaxneuvance, Capvaxive |
| Exact Sciences Corporation | $133.23 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.85 | 2024-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $86.00 | 2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $48.54 | 2024-2025 | Xifaxan |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $30.51 | 2024 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $26.75 | 2022 | |
| Ardelyx, INC. | $26.42 | 2025 | Ibsrela |
| Boston Scientific Corporation | $20.36 | 2024 | Watchman Flx |
| Shield Therapeutics INC | $18.21 | 2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $17.76 | 2022 | |
| Novartis Pharmaceuticals Corporation | $17.32 | 2022 | |
| Sanofi Pasteur INC. | $14.80 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tanya Sargent listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.